Meta-analysis with Variance Components

2017 ◽  
pp. 185-193
Author(s):  
Ton J. Cleophas ◽  
Aeilko H. Zwinderman
2021 ◽  
Author(s):  
Donald Ray Williams ◽  
Josue E. Rodriguez ◽  
Paul - Christian Bürkner

We shed much needed light upon a critical assumption that is oft-overlooked---or not considered at all---in random-effects meta-analysis.Namely, that between-study variance is constant across \emph{all} studies which implies they are from the \emph{same} population. Yet it is not hard to imagine a situation where there are several and not merely one population of studies, perhaps differing in their between-study variance (i.e., heteroskedasticity). The objective is to then make inference, given that there are variations in heterogeneity. There is an immediate problem, however, in that modeling heterogeneous variance components is not straightforward to do in a general way. To this end, we propose novel methodology, termed Bayesian location-scale meta-analysis, that can accommodate moderators for both the overall effect (location) and the between-study variance (scale). After introducing the model, we then extend heterogeneity statistics, prediction intervals, and hierarchical shrinkage, all of which customarily assume constant heterogeneity, to include variations therein. With these new tools in hand, we go to work demonstrating that quite literally \emph{everything} changes when between-study variance is not constant across studies. The changes were not small and easily passed the interocular trauma test---the importance hits right between the eyes. Such examples include (but are not limited to) inference on the overall effect, a compromised predictive distribution, and improper shrinkage of the study-specific effects. Further, we provide an illustrative example where heterogeneity was not considered a mere nuisance to show that modeling variance for its own sake can provide unique inferences, in this case into discrimination across nine countries. The discussion includes several ideas for future research. We have implemented the proposed methodology in the {\tt R} package \textbf{blsmeta}.


2019 ◽  
Author(s):  
Klaus Munkholm ◽  
Stephanie Winkelbeiner ◽  
Philipp Homan

Background. The observation that some patients appear to respond better to antidepressants for depression than others encourages the assumption that the effect of antidepressants differs between individuals and that treatment can be personalized. To test this assumption, we compared the outcome variance in the group of patients receiving antidepressants with the outcome variance of the group of patients receiving placebo in randomized controlled trials (RCTs) of adults with major depressive disorder (MDD). An increased variance in the antidepressant group would indicate individual differences in response to antidepressants. In addition, we illustrate in a simulation study why attempts to personalize antidepressant treatment using RCTs might be misguided.Methods. We first illustrated the variance components of trials by simulating RCTs and crossover trials of antidepressants versus placebo. Second, we analyzed data of a large meta-analysis of antidepressants for depression, including a total of 222 placebo-controlled studies from the dataset that reported outcomes on the 17 or 21 item Hamilton Depression Rating Scale or the Montgomery-Åsberg Depression Rating Scale. We performed inverse variance, random-effects meta-analyses of the variability ratio (VR) between the antidepressant and placebo groups. Outcomes. The meta-analyses of the VR comprised 345 comparisons of 19 different antidepressants with placebo in a total of 61144 adults with an MDD diagnosis. Across all comparisons, we found no evidence for a larger variance in the antidepressant group compared with placebo overall (VR = 1.00, 95% CI: 0.98; 1.01, I2 = 0%) or for any individual antidepressant. Interpretation. Our findings did not provide empirical support for individual differences in response to antidepressants.


2021 ◽  
Author(s):  
Yali Wei ◽  
Yan Meng ◽  
Na Li ◽  
Qian Wang ◽  
Liyong Chen

The purpose of the systematic review and meta-analysis was to determine if low-ratio n-6/n-3 long-chain polyunsaturated fatty acid (PUFA) supplementation affects serum inflammation markers based on current studies.


Sign in / Sign up

Export Citation Format

Share Document